Have a personal or library account? Click to login
Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental? Cover

Antidiabetic drugs and the risk of cancer: beneficial, neutral, or detrimental?

Forum of Clinical Oncology
Volume 12 (2021): Issue 1 (May 2021)
By: Taoreed Adegoke Azeez,  Sharif Adeniyi Folorunso,  Chinedu Eguzozie and  Adeleke Adedapo Adegboyega  
Open Access
|Aug 2021

Authors

Taoreed Adegoke Azeez

adegokegalaxy@yahoo.com

Endocrinology, Metabolism and Diabetes Unit, Department of Medicine, University College Hospital, Ibadan, Nigeria

Sharif Adeniyi Folorunso

Department of Radiation Oncology, University College Hospital, Ibadan, Nigeria

Chinedu Eguzozie

Endocrinology, Metabolism and Diabetes Unit, Department of Medicine, University College Hospital, Ibadan, Nigeria

Adeleke Adedapo Adegboyega

Department of Clinical Pharmacology, University College Hospital, Ibadan, Nigeria
DOI: https://doi.org/10.2478/fco-2021-0014 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 74 - 81
Submitted on: Aug 4, 2020
Accepted on: Sep 21, 2020
Published on: Aug 9, 2021
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
antidiabetic drugs,
diabetes,
cancer
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2021 Taoreed Adegoke Azeez, Sharif Adeniyi Folorunso, Chinedu Eguzozie, Adeleke Adedapo Adegboyega, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 12 (2021): Issue 1 (May 2021)Next article